Analyst Profile

Followed by 81 followers
.
Chris Schott

Chris Schott

J.P. Morgan
Wall Street Analyst
#5,198 out of 8,141 Wall Street Analysts
#14,748 out of 24,284 experts

Success Rate

52%
118 out of 229 transactions made a profit

Average Return

0.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Chris Schott's trades since 2013 and holding each position for 1 Year would result in 51.53% of your transactions generating a profit, with an average return of 0.0% per rating.

Stock Rating Distribution

395Ratings
63.04% Buy
33.92% Hold
3.04% Sell
Distribution of Chris Schott's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
United KingdomUK Market

Best Rating

Stock:
Bausch Health Companies
(BHC)
Rating:Buy
Date:Mar 20, 2013 - Mar 20, 2014
Return:+91.40%
The most profitable rating made by Chris Schott

Chris Schott's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
KYTH
Kythera
Sep 16, 2013
Buy
Assigned
1Ratings
100%
+6.80%
Amarin
Oct 17, 2013
Hold
Downgraded
1Ratings
0.00%
~FRX
Forest Labs
Feb 04, 2014
Buy
Upgraded
3Ratings
33%
+5.20%
HSP
Hospira Inc
Dec 31, 2014
Hold
Assigned
3Ratings
0.00%
SGNT
Sagent Pharm
Jan 06, 2016
Hold
Assigned
2Ratings
0.00%
MNTA
Momenta Pharma
Oct 04, 2017
Buy
Reiterated
6Ratings
100%
+34.37%
Kala Pharmaceuticals
Nov 17, 2017
Buy
Reiterated
$35.00
(521.67% Upside)
3Ratings
0%
-52.57%
Endo International
May 13, 2019
Sell
Downgraded
$9.00
(9074.31% Upside)
16Ratings
25%
-31.12%
Sienna Biopharmaceuticals
May 13, 2019
Hold
Downgraded
2Ratings
0%
-22.90%
AGN
Allergan
Jun 19, 2019
Buy
Reiterated
25Ratings
57%
+13.83%
List of latest recommendations made by Chris Schott. Click to expand and see Chris Schott's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >